Pfizer Inc. (NYSE:PFE) Shares Purchased by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,809 shares of the biopharmaceutical company’s stock after acquiring an additional 5,917 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Pfizer were worth $2,807,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Empirical Asset Management LLC increased its holdings in Pfizer by 383.4% in the 4th quarter. Empirical Asset Management LLC now owns 49,622 shares of the biopharmaceutical company’s stock worth $1,316,000 after buying an additional 39,356 shares during the period. Edge Wealth Management LLC grew its stake in shares of Pfizer by 6.2% during the 4th quarter. Edge Wealth Management LLC now owns 8,517 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 500 shares during the period. Werlinich Asset Management LLC grew its stake in shares of Pfizer by 2.6% during the 4th quarter. Werlinich Asset Management LLC now owns 92,735 shares of the biopharmaceutical company’s stock worth $2,450,000 after purchasing an additional 2,350 shares during the period. Cohen Investment Advisors LLC grew its stake in shares of Pfizer by 4.5% during the 4th quarter. Cohen Investment Advisors LLC now owns 78,409 shares of the biopharmaceutical company’s stock worth $2,080,000 after purchasing an additional 3,343 shares during the period. Finally, Tallon Kerry Patrick acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $509,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.1 %

Shares of NYSE:PFE opened at $26.51 on Friday. The business has a 50-day moving average price of $26.11 and a 200 day moving average price of $28.01. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) EPS. Sell-side analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.